You have 9 free searches left this month | for more free features.

inactivated-adjuvanted SARS-CoV-2 virus vaccine

Showing 51 - 75 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

SARS-CoV-2 Trial in Chengdu (RBMRNA-176, Placebo)

Active, not recruiting
  • SARS-CoV-2
  • RBMRNA-176
  • Placebo
  • Chengdu, Sichuan, China
    Chengdu Xinhua Hospital affiliated to North Sichuan Medical Coll
Jun 12, 2023

SARS-CoV-2 Virus Trial in Bangkok (SARS-CoV-2 RNA detection)

Completed
  • SARS-CoV-2 Virus
  • SARS-CoV-2 RNA detection
  • Bangkok, Thailand
    2 Division of Nephrology,Department of Medicine Pramongkutklao H
Aug 31, 2023

COVID-19, Vaccines Trial in Santiago (CoronaVac®, Omicron Vaccine, Trivalent Vaccine)

Recruiting
  • COVID-19
  • Vaccines
  • CoronaVac®
  • +2 more
  • Santiago, Metropolitana, Chile
  • +2 more
Jan 12, 2023

Covid19 Trial in Cypress (VXA-CoV2-1)

Completed
  • Covid19
  • VXA-CoV2-1
  • Cypress, California
    WCCT
Jan 17, 2023

COVID-19 Virus Infection Trial in Ciudad Autónoma de Buenos Aires (Inactivated SARS-CoV-2 vaccine (Vero cell), Placebo/Aluminum

Completed
  • COVID-19 Virus Infection
  • Inactivated SARS-CoV-2 vaccine (Vero cell)
  • Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine
  • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
  • +3 more
Jan 11, 2022

COVID-19 Trial in Xi'an (Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2, Inactivated SARS-CoV-2 Vaccine

Active, not recruiting
  • COVID-19
  • Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2
  • +6 more
  • Xi'an, Shanxi, China
    Yaliang county Center for Disease Control and Prevention
Dec 13, 2021

COVID-19 Trial in United States (XBB.1.5 Vaccine (Booster), XBB.1.5 Vaccine (single dose))

Not yet recruiting
  • COVID-19
  • XBB.1.5 Vaccine (Booster)
  • XBB.1.5 Vaccine (single dose)
  • Mobile, Alabama
  • +29 more
Aug 4, 2023

Sars-CoV-2 Infection Trial in Negrar (Nasal and mouth swab)

Active, not recruiting
  • Sars-CoV-2 Infection
  • Nasal and mouth swab
  • Negrar, Verona, Italy
    IRCCS Sacro Cuore Don Calabria hospital
Mar 14, 2023

SARS-CoV-2 Trial (SARS-CoV-2 variant mRNA vaccine low dose, SARS-CoV-2 variant mRNA vaccine high dose)

Not yet recruiting
  • SARS-CoV-2
  • SARS-CoV-2 variant mRNA vaccine low dose
  • SARS-CoV-2 variant mRNA vaccine high dose
  • (no location specified)
Oct 30, 2022

SARS-CoV2 Infection Trial in Mile (SARS-CoV-2 Vaccine, Inactivated (Vero Cell))

Recruiting
  • SARS-CoV2 Infection
  • SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
  • Mile, Yunnan, China
    Mile City Centers for Disease Control and Prevention
Feb 14, 2022

SARS CoV 2 Infection, Influenza, Human Trial in Spain (BIMERVAX, SIIV)

Not yet recruiting
  • SARS CoV 2 Infection
  • Influenza, Human
  • BIMERVAX
  • SIIV
  • Santiago De Compostela, A Coruña, Spain
  • +7 more
Aug 8, 2023

SARS-CoV-2 Vaccine in Metabolism-related Fatty Liver Disease

Not yet recruiting
  • Metabolic Associated Fatty Liver Disease
  • Recombinant protein vaccine and adenovirus vector vaccine
  • (no location specified)
Feb 12, 2023

COVID-19 Trial (NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg))

Not yet recruiting
  • COVID-19
  • NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine
  • Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
  • (no location specified)
Aug 4, 2023

COVID-19, SARS-CoV-2 Trial in Seoul (QTP104 1ug, QTP104 5ug, QTP104 25ug)

Active, not recruiting
  • COVID-19
  • SARS-CoV-2
  • QTP104 1ug
  • +2 more
  • Seoul, Korea, Republic of
  • +1 more
May 24, 2023

SARS-CoV-2 Infection Trial in Groningen, Utrecht, Auckland (VLA2001)

Active, not recruiting
  • SARS-CoV-2 Infection
  • VLA2001
  • Groningen, Netherlands
  • +3 more
Jan 17, 2023

Humoral and Cellular Immunity Against SARS-COV-2 Vaccine in

Active, not recruiting
  • SARS-CoV-2 RNA Vaccines
  • HIV Infection
  • SARS-CoV-2 Vaccine
  • Sevilla, Spain
    Virgen del Rocio University Hospital
Dec 1, 2022

COVID-19 Trial in Langhorne (BBV152)

Available
  • COVID-19
  • BBV152
  • Langhorne, Pennsylvania
    Woods
Sep 14, 2022

SARS-CoV-2 Infection Trial in Anning (SARS-CoV-2 Vaccine, Inactivated (Vero Cell))

Recruiting
  • SARS-CoV-2 Infection
  • SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
  • Anning, Yunnan, China
    Anning First People's Hospital
Feb 14, 2022

SARS-CoV-2 Trial (SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high

Not yet recruiting
  • SARS-CoV-2
  • SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose
  • +2 more
  • (no location specified)
Dec 1, 2022

COVID-19 Trial (SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated)

Not yet recruiting
  • COVID-19
  • SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated
  • (no location specified)
Dec 23, 2021

SARS-CoV-2 Trial in Bengbu (SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA

Active, not recruiting
  • SARS-CoV-2
  • SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose
  • +2 more
  • Bengbu, Anhui, China
    First Affiliated Hospital Bengbu Medical College
Jan 3, 2023

COVID-19 Trial in Vitória (Inactivated Coronavac/Butantan vaccine, BNT162b2 (Pfizer))

Recruiting
  • COVID-19
  • Inactivated Coronavac/Butantan vaccine
  • BNT162b2 (Pfizer)
  • Vitória, Espírito Santo, Brazil
    Valéria Valim
Feb 1, 2022

COVID-19 Trial ("Sputnik Lite" vaccine for the prevention of COVID-19 with altered antigenic composition)

Not yet recruiting
  • COVID-19
  • "Sputnik Lite" vaccine for the prevention of COVID-19 with altered antigenic composition
  • (no location specified)
Sep 26, 2023

COVID-19 Trial in Barranquilla, Cali (Candidate vaccine, SCB-2019)

Not yet recruiting
  • COVID-19
  • Candidate vaccine, SCB-2019
  • Barranquilla, Colombia
  • +1 more
Aug 23, 2022

Immunogenicity ofThird-dose Booster After Two Doses

Recruiting
  • COVID-19
  • Vaccine Reaction
  • an inactivated SARS-CoV-2 vaccine named BBIBP-CorV
  • Shanghai, China
    Infectious department of Huashan Hospital, Fudan University
Aug 7, 2022